ASH News Daily 2014 - Day 3 - (Page A-1)

Read this issue online at Follow us on Twitter using #ASH14 Schedule 9:00 - 10:00 a.m. E. Donnall Thomas Lecture Moscone North, Hall D 10:30 a.m. - 12:00 noon Spotlight Sessions: Controversy: What is the Best Preclinical Model for Testing Novel Therapeutics? Venous Thromboembolism in Vulnerable Populations Moscone South, Esplanade 301-302 12:15 - 1:15 p.m. Featured Topic Discussion: Checkpoint Blockades Moscone North, Rooms 120-125 12:15 - 1:15 p.m. Meet the Blood Editors Marriott Marquis, Pacific I 1:30 - 2:30 p.m. Ernest Beutler Lecture Moscone North, Hall D 2:45 - 4:15 p.m. Spotlight Sessions: Novel Agents for T-Cell Lymphoma Weed or Soil: The Malignant Bone Marrow Niche Moscone South, Esplanade 301-302 4:30 - 6:00 p.m. Special Education Session: Newly Approved Drugs Moscone North, Hall D This CAR-T Has Wheels! By laura MichaeliS, Md I n the world of hematologic malignancies, seismic shifts in treatment strategies are uncommon. While rare, these shifts do happen - stem cell transplantation, imatinib, and ATRA come to mind as some of the disruptive technologies that have allowed patient care to accelerate along a totally new trajectory. The accumulating data supporting chimeric antigen receptor T-cell (CAR-T) therapy for diseases such as chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) highlight what may well become the next sea change in the care of patients with all types of hematologic neoplasia. Yesterday's standing-room-only scientific symposium on CAR-T cell therapy bespoke some of the mounting enthusiasm regarding this new treatment strategy. The symposium featured Dr. Carl June, the lead translational investigator for the University of Pennsylvania's study of engineered T-lymphocytes in the treatment of patients with relapsed CLL, ALL, and non-Hodgkin lymphoma. Those studies and others being done at the Dr. Steven Rosenberg presents during the Special Scientific Symposium on Chimeric Antigen Receptor T-Cell Therapy Sunday. National Institutes of Health (NIH), Children's Hospital of Pennsylvania, and Memorial Sloan Kettering paved the way for several larger studies, most notably those performed in relapsed/refractory ALL. Dr. June's discussion not only recapped some of what has been accomplished in the care of patients with lymphoid neoplasms, but also outlined other possible suitable antigen target cells, with the hope that this type of approach will be scalable with minimal toxicity. "We're hoping for a fleet of CARs," Dr. June quipped in response to a question from the audience about the next likely antigens that may be investigated. He also pointed to the fact that the chimeric cells can recognize even small amounts of »» CAR-T Page A-18 Globulins du Chyle: What Have We Learned About Platelets Since 1842? IN THIS SECTION Sunday's Plenaries A-2 Congenital Cures A-4 Von Willebrand Disease A-4 ASH/EHA Joint Symposium A-5 By reBecca KruSe-JarreS, Md, MPh n a publication from 1842, Alfred Donne, a French physician, experimenter, microscopist, and photographer observed, "Il existe dans le sang trois espèces de particules." Besides the "globules rouge" and "globules blancs" he described the "globulins du chyle" - small globules derived from plasma. James Wright (using the stain named after him) further examined and characterized these plasma globules and coined them platelets in 1910. The »» PLATELETS Page A-19 I

Table of Contents for the Digital Edition of ASH News Daily 2014 - Day 3

Table of Contents

ASH News Daily 2014 - Day 3